Summary of Study ST001795
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001139. The data can be accessed directly via it's Project DOI: 10.21228/M8GH59 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST001795 |
Study Title | Changes in mesenteric lymph lipid profile of mice upon high-fat diet with and without Celecoxib (part I) |
Study Type | Untargeted lipidomics analysis |
Study Summary | Untargeted lipid profiling of mesenteric mice lymph from mice fed with CHOW, HFD and HFD supplemented with COx-2 inhibitor drug Celecoxib. It is proposed that Celecoxib can protect from deleterious morphological changes in lymphatic system caused by obesity/HFD. |
Institute | Monash Institute of Pharmaceutical Sciences |
Department | Drug Delivery, Disposition and Dynamics |
Laboratory | Trevaskis Lab, Creek Lab |
Last Name | Anderson |
First Name | Dovile |
Address | 6 Anderson |
dovile.anderson@gmail.com | |
Phone | 8671141 |
Submit Date | 2021-05-12 |
Num Groups | 3 |
Total Subjects | 26 |
Num Males | 26 |
Publications | Manuscript NATMETAB-A20022406A Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential novel treatment target in obesity |
Raw Data Available | Yes |
Raw Data File Type(s) | raw(Thermo) |
Analysis Type Detail | LC-MS |
Release Date | 2021-06-02 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
Project ID: | PR001139 |
Project DOI: | doi: 10.21228/M8GH59 |
Project Title: | Changes in mesenteric lymph lipid profile of mice upon high-fat diet with and without Celecoxib |
Project Type: | Untargeted lipidomics |
Project Summary: | Untargeted lipidomic profiling of mice mesenteric lymph upon HFD diet and HFD supplemented with COX-2 inhibitor drug Celecoxib. It is proposed that Celecoxib can rescue from negative morphological changes induced by obesity/HFD diet in lymphatic system. |
Institute: | Monash Institute of Pharmaceutical Sciences |
Department: | Drug Delivery, Disposition and Dynamics |
Laboratory: | Trevaskis Lab, Creek Lab |
Last Name: | Anderson |
First Name: | Dovile |
Address: | 399 Royal Pd |
Email: | dovile.anderson@monash.edu |
Phone: | +61448671141 |
Funding Source: | Department of Health | National Health and Medical Research Council (NHMRC) - 1100036 [Trevaskis] |
Project Comments: | This lipidomics project is part of a larger obesity/lymph research as described in the manuscript |
Publications: | Manuscript NATMETAB-A20022406A Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential novel treatment target in obesity |
Contributors: | Dr Enyuan Cao , Matthew Watt , Cameron Nowell , Dr Tim Quach , Jamie Simpson , Ms Violena Ferreira , Sonya Argawal , Hannah Chu , Anubhav Srivastava , Dr Dovile Anderson , Gracia Gracia , Alina Lam , Gabriela Segal , Jiwon Hong , Dr Luojuan Hu , Kian Lium Phang , Alistair Escott , Professor John Windsor , Anthony Phillips , Darren Creek , Professor Natasha Harvey , Professor Christopher Porter |